Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vical makes two appointments to board

This article was originally published in Scrip

Executive Summary

Vical, a company developing biopharmaceutical products based on DNA delivery technologies, has appointed Richard Beleson and Stephen Sherwin to its board of directors. Mr Beleson retired as senior vice-president of Capital Group Companies in 2010, where previously he was an equity investment analyst and institutional investor focused on the biotechnology and pharmaceutical industries. Mr Sherwin is a clinical professor of medicine at the University of California, San Francisco. He is co-founder and chair of the board of directors at Ceregene and a member of the boards of Biogen Idec, BioSante Pharmaceuticals, Neurocrine Biosciences, Rigel Pharmaceuticals, and Verastem. He is also a member of the board and chair Emeritus of the Biotechnology Industry Organization.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts